These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 18161391)

  • 21. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
    Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
    Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Liao EP
    Am J Med; 2012 Oct; 125(10):S1-2. PubMed ID: 22998891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of depression on health care utilization and costs in patients with type 2 diabetes.
    Kalsekar ID; Madhavan SM; Amonkar MM; Scott V; Douglas SM; Makela E
    Manag Care Interface; 2006 Mar; 19(3):39-46. PubMed ID: 16583789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.
    Cheong C; Barner JC; Lawson KA; Johnsrud MT
    Clin Ther; 2008 Oct; 30(10):1893-907. PubMed ID: 19014846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
    Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
    Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the socioeconomic status on the probability of receiving formulary restricted thiazolidine (TZDs).
    Dorais M; LeLorier J
    Can J Clin Pharmacol; 2008; 15(1):e15-21. PubMed ID: 18184984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
    Hsu CC; Wahlqvist ML; Lee MS; Tsai HN
    J Alzheimers Dis; 2011; 24(3):485-93. PubMed ID: 21297276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.
    Desai NR; Shrank WH; Fischer MA; Avorn J; Liberman JN; Schneeweiss S; Pakes J; Brennan TA; Choudhry NK
    Am J Med; 2012 Mar; 125(3):302.e1-7. PubMed ID: 22340932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 32. Oral combination therapy with thiazolidinediones in type 2 diabetes.
    LaSalle JR; Cross LB
    Am J Manag Care; 2006 Nov; 12(14 Suppl):S369-81. PubMed ID: 17112324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
    Charbonnel B
    Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
    [No Abstract]   [Full Text] [Related]  

  • 34. Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance.
    Roselli A; Hayes JD; Seidner R; Marchione V; Snyder CM; Mayes K; Stiernberg CM; Milgram L
    Manag Care; 2001 Feb; 10(2 Suppl):17-21. PubMed ID: 11729404
    [No Abstract]   [Full Text] [Related]  

  • 35. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follow-up of intensive glucose control in type 2 diabetes.
    Petrie JR
    N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672
    [No Abstract]   [Full Text] [Related]  

  • 37. [Effect of short-term intensive therapy with glimepiride and metformin in newly diagnosed type 2 diabetic patients].
    WANG M; GAO F; XUE YM; HAN YJ; FU XJ; HE FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Mar; 31(3):564-6. PubMed ID: 21421509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
    Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
    J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distal upper and lower limb fractures associated with thiazolidinedione use.
    Jones SG; Momin SR; Good MW; Shea TK; Patric K
    Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.